47 102

Cited 0 times in

Regression of liver fibrosis and hepatocellular carcinoma development after HCV eradication with oral antiviral agents

Authors
 Hae Won Yoo  ;  Jun Yong Park  ;  Sang Gyune Kim  ;  Young Kul Jung  ;  Sae Hwan Lee  ;  Moon Young Kim  ;  Dae Won Jun  ;  Jae Young Jang  ;  Jin Woo Lee  ;  Oh Sang Kwon 
Citation
 SCIENTIFIC REPORTS, Vol.12(1) : 193, 2022-01 
Journal Title
SCIENTIFIC REPORTS
Issue Date
2022-01
MeSH
Administration, Oral ; Aged ; Antiviral Agents / administration & dosage* ; Antiviral Agents / adverse effects ; Carbamates / administration & dosage ; Carcinoma, Hepatocellular / diagnosis ; Carcinoma, Hepatocellular / epidemiology ; Carcinoma, Hepatocellular / prevention & control* ; Carcinoma, Hepatocellular / virology ; Drug Therapy, Combination ; Elasticity Imaging Techniques ; Female ; Hepatitis C, Chronic / diagnosis ; Hepatitis C, Chronic / drug therapy* ; Hepatitis C, Chronic / epidemiology ; Hepatitis C, Chronic / virology ; Humans ; Imidazoles / administration & dosage ; Incidence ; Interferons / administration & dosage ; Isoquinolines / administration & dosage ; Liver Cirrhosis / diagnostic imaging ; Liver Cirrhosis / drug therapy* ; Liver Cirrhosis / epidemiology ; Liver Cirrhosis / virology ; Liver Neoplasms / diagnosis ; Liver Neoplasms / epidemiology ; Liver Neoplasms / prevention & control* ; Liver Neoplasms / virology ; Male ; Middle Aged ; Prospective Studies ; Pyrrolidines / administration & dosage ; Retrospective Studies ; Ribavirin / administration & dosage ; Seoul ; Sulfonamides / administration & dosage ; Sustained Virologic Response ; Time Factors ; Treatment Outcome ; Valine / administration & dosage ; Valine / analogs & derivatives
Abstract
We prospectively investigated the changes of liver stiffness (LS) and the occurrence of hepatocellular carcinoma (HCC) after hepatitis C virus (HCV) eradication using direct antiviral agents (DAA) over three years. LS measurement using transient elastography and serum fibrosis surrogate markers before treatment and at 48, 96, 144 weeks after starting direct-acting antivirals (DAA) according to the protocol were evaluated. Patients were also compared with historical cohort treated with pegylated interferon (peg-IFN). Sustained viral response (SVR) was observed in 95.8%. LS value in the patients achieving SVR significantly decreased over time (19.4 ± 12.9 kPa [baseline], 13.9 ± 9.1 kPa [48 weeks], 11.7 ± 8.2 kPa [96 weeks], 10.09 ± 6.23 [144 weeks], all p < 0.001). With matched analysis, the decrease in LS value was significantly larger in DAA group than peg-IFN group at both 48 weeks (29% vs. 9%) and 96 weeks (39% vs. 17%). The incidence of HCC was not significantly different between DAA and peg-IFN groups (5.5% vs. 5.4%) at 144 weeks. HCV eradication with DAA can lead to improvement of liver stiffness over time. The regression of fibrosis was greater in the group with DAA than peg-IFN.Clinical trials registration: ClinicalTrials.gov (NCT02865369).
Files in This Item:
T202200878.pdf Download
DOI
10.1038/s41598-021-03272-1
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Park, Jun Yong(박준용) ORCID logo https://orcid.org/0000-0001-6324-2224
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/188330
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links